Menopur (Menotrophin)

Menotrophin provides both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity. The FSH component binds to receptors on granulosa cells, promoting follicle recruitment and estrogen synthesis, while the LH component activates theca cells and supports the final maturation of the dominant follicle and ovulation. The combined action mimics the natural pituitary surge required for oocyte development.

The dosage of Menopur is individualized and determined by the prescribing physician based on the patient’s ovarian reserve, response to prior stimulation, and the specific treatment protocol. The prescriber calculates the appropriate number of international units per injection and adjusts the regimen according to ultrasound and hormone monitoring throughout the cycle.

Menopur is intended for use before conception to induce ovulation; it is not administered during an established pregnancy. Its safety in pregnancy has not been established, and it is generally avoided once pregnancy is confirmed. Limited data are available regarding use during breastfeeding, and the drug is typically discontinued before lactation begins.

To request Menopur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details—including cold‑chain handling if needed—and assists with any required import documentation.

Menopur differs from recombinant FSH products by providing a combination of FSH and LH activity in a single preparation, which can simplify dosing for patients who require both hormones. Compared with pure FSH agents, Menopur may achieve comparable follicular response while reducing the need for separate LH supplementation, but individual response varies and treatment choice depends on the clinician’s assessment.

Menopur should be stored at 2‑8 °C (refrigerated) in its original packaging. It must be protected from light and should never be frozen or shaken. If the product is removed from refrigeration for a short period during administration, it should be returned to the refrigerator promptly and used within the time frame specified in the labeling.

Menopur is supplied as a sterile solution for subcutaneous injection. The prescribed dose is drawn into a sterile syringe and injected into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique. Injections are usually given once daily, but the exact schedule is determined by the treating physician based on the stimulation protocol.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal distension, shortness of breath, and, in rare cases, thromboembolic events or ovarian torsion. Anaphylactic reactions, though uncommon, may also occur. Patients should be monitored closely for signs of these complications, and treatment should be stopped if severe adverse events arise.

Menopur is contraindicated in women who are pregnant, have known hypersensitivity to menotrophin or any component of the formulation, have active ovarian cysts, or have uncontrolled endocrine disorders that increase the risk of OHSS. It should also be avoided in patients with severe liver or kidney disease, and in those for whom ovarian stimulation is not medically indicated.